Printer Friendly

FDA COMPLETES REVIEW OF CARDENE SR

 FDA COMPLETES REVIEW OF CARDENE SR
 PALO ALTO, Calif., Jan. 23 /PRNewswire/ -- Syntex Corp.


(NYSE: SYN) said today that it has received an "approvable" letter from the United States Food and Drug Administration (FDA), indicating that the FDA has completed its review of Syntex's New Drug Application for approval to market a sustained release formulation of Cardene (nicardipine hydrochloride) for the treatment of hypertension.
 Upon conclusion of final labeling discussions with the FDA, Syntex expects to be granted final approval to market Cardene SR. Syntex declined to speculate when final marketing approval may be granted.
 Syntex has marketed Cardene, a prescription calcium channel blocker taken in capsule form three times a day for the treatment of angina and hypertension, in the United States since March 1989. Cardene SR capsules, when approved for marketing, would be prescribed for use twice a day.
 Syntex is a multinational healthcare company that discovers, develops, manufactures and markets prescription medicines that treat serious human diseases. Syntex also develops, manufactures and markets animal pharmaceutical products and medical diagnostic systems.
 -0- 1/23/92
 /CONTACT: Linda Thomas, 415-852-1321; or Jan R. Potts, 415-855-5052, both of Syntex Corp./
 (SYN) CO: Syntex Corp. ST: California IN: MTC SU:


RM -- SJ007 -- 2877 01/23/92 14:13 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 23, 1992
Words:208
Previous Article:LOCKHEED APPOINTS ROBERT E. RULON VICE PRESIDENT AND CONTROLLER
Next Article:FANNIE MAE PRICES $228 MILLION REMIC MANAGED BY BEAR STEARNS; CALIFORNIA STATE TREASURER TO PURCHASE $100 MILLION OF REMIC
Topics:


Related Articles
WISCONSIN PHARMACAL COMPANY FEMALE CONDOM APPLICATION SCHEDULED FOR ADVISORY PANEL REVIEW
W-L RECEIVES LETTER FROM FDA ON LOPID SR, CALLING INTO QUESTION COMPANY'S ABILITY TO OBTAIN TIMELY APPROVAL FOR CERTAIN INDICATIONS
SYNTEX RECEIVES FDA APPROVAL TO MARKET CARDENE(R) SR FOR TREATING HYPERTENSION
FDA APPROVES MARKETING OF SYNTEX'S CYTOVENE FOR ADDITIONAL INDICATION -- PREVENTION OF CMV INFECTION IN TRANSPLANT PATIENTS
'WE'RE INVESTING NOW FOR FUTURE GROWTH,'SYNTEX TELLS ANALYSTS
GUILFORD PHARMACEUTICALS' NEW DRUG APPLICATION FOR GLIADEL ACCEPTED FOR REVIEW BY THE FDA
MYOTROPHIN SCHEDULED FOR JUNE FDA ADVISORY PANEL MEETING

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters